Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities
Status:
Completed
Trial end date:
2017-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the ability of new anti-HIV agents to penetrate
different body compartments in HIV negative men who have sex with men and transgender women.
These new agents might be considered for pre-exposure prophylaxis regimens in the future.
This study will include 90 healthy, HIV-negative men who have sex with men and transgender
women who are not taking hormones aged 18-49 years. Participant must be willing to
participate in 1 of the 3 study phases, be willing to take Truvada® (PrEP) or Genvoya®, and
willing to undergo blood draws, urethral swabs, and rectal biopsy procedures.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborator:
Centers for Disease Control and Prevention
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination